Virpax Pharmaceuticals Inc Stock

$0.61

4.72% yesterday

Nasdaq, Nov 15, 10:00 pm CET

ISIN

US9282511073

Symbol

VRPX

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Virpax Pharmaceuticals Inc Stock price

$0.61

-99.39 99.39% 5Y

Nasdaq, Closing price Fri, Nov 15 2024

-0.03 4.72%

ISIN

US9282511073

Symbol

VRPX

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Market capitalization	$3.00m
Enterprise Value	$1.13m
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	negative
P/B ratio (TTM) P/B ratio	negative
Revenue (TTM) Revenue	$0.00
EBIT (operating result TTM) EBIT	$-17.56m
Free Cash Flow (TTM) Free Cash Flow	$-15.04m
Cash position	$1.87m
EPS (TTM) EPS	$-13.51
P/E forward	negative
Short interest	7.65%

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

Get Started for Free Today

Virpax Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

??

1 Analyst has issued a forecast Virpax Pharmaceuticals Inc:

1x Buy

100%

More details on Analyst Estimates Including Price Targets

1 Analyst has issued a forecast Virpax Pharmaceuticals Inc:

Buy

100%

Analyst Estimates with Stock Price Targets

Financial data from Virpax Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Jun '24		+/- %
Revenue	- -	- 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	11 11	11% 11% -
- Research and Development Expense	6.16 6.16	8% 8% -
EBITDA	-18 -18	4% 4% -
- Depreciation and Amortization	- -	- -
EBIT (Operating Income) EBIT	-18 -18	4% 4% -
Net Profit	-17 -17	13% 13% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Virpax Pharmaceuticals Inc Stock News

Neutral

Business Wire

●

about 5 hours ago

Virpax Pharmaceuticals, Inc. Announces Closing of $5.0 Million Public Offering of Common Stock and Pre-Funded Warrants

BERWYN, Pa.--(BUSINESS WIRE)--Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”), a preclinical-stage pharmaceutical company focused in novel and proprietary drug delivery systems across various pain indications, announced today the closing of its public offering of $5.0 million of shares of the Company's common stock, par value $0.00001 per share, and pre-funded warrants t...

Neutral

Business Wire

●

2 days ago

Virpax Pharmaceuticals, Inc. Announces Pricing of $5.0 Million Public Offering of Common Stock and Pre-Funded Warrants

BERWYN, Pa.--(BUSINESS WIRE)--Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”), a preclinical-stage pharmaceutical company focused in novel and proprietary drug delivery systems across various pain indications, announced today the pricing of its public offering of $5.0 million of shares of the Company's common stock, par value 0.00001 per share, and/or pre-funded warrants...

Neutral

Business Wire

●

4 months ago

Virpax Regains Compliance with Nasdaq Minimum Bid Price

BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax Regains Compliance with Nasdaq Minimum Bid Price.

More Virpax Pharmaceuticals Inc News

Company Profile

Virpax Pharmaceuticals, Inc. is a preclinical stage biopharmaceutical company, which engages in the development of branded, non-addictive pain management products. Its products include metered-dose spray, liposomal gel encapsulates, and intranasal spray. The company was founded by Anthony P. Mack and Jeffrey A. Gudin in 2016 and and is headquartered in Berwyn, PA.

Head office	United States
CEO	Jay Dhaliwal
Employees	7
Founded	2016
Website	www.virpaxpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now